BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37437037)

  • 1. Prognostic value of RGS1 and mTOR Immunohistochemical expression in Egyptian multiple myeloma patients; A single center study.
    Hafez N; Refaat L; ElGebaly OK; Elhariry HM; Ghareeb M; Fathalla LA
    PLoS One; 2023; 18(7):e0288357. PubMed ID: 37437037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RGS1 expression is associated with poor prognosis in multiple myeloma.
    Roh J; Shin SJ; Lee AN; Yoon DH; Suh C; Park CJ; Huh J; Park CS
    J Clin Pathol; 2017 Mar; 70(3):202-207. PubMed ID: 27445341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical Expression of mTOR in Multiple Myeloma: Retrospective Analysis of 31 Cases, a Clinicopathological Study.
    Stockwin W; Johnson P; Vajpayee N
    Ann Clin Lab Sci; 2016; 46(2):125-31. PubMed ID: 27098617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
    Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
    Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel role for RGS1 in melanoma progression.
    Rangel J; Nosrati M; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
    Am J Surg Pathol; 2008 Aug; 32(8):1207-12. PubMed ID: 18580492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the Clinicopathological Parameters Affecting the Outcome in Egyptian Patients with Multiple Myeloma.
    Sallam YA; Samra MA; Gaber AA
    Gulf J Oncolog; 2016 Jan; 1(20):51-63. PubMed ID: 27050180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of P-selectin glycoprotein ligand-1 to prognosis in patients with multiple myeloma.
    Atalay F; Ateşoğlu EB; Yıldız S; Firatlı-Tuglular T; Karakuş S; Bayık M
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):164-70. PubMed ID: 25445472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-215-5p is an anticancer gene in multiple myeloma by targeting RUNX1 and deactivating the PI3K/AKT/mTOR pathway.
    Liu S; Zhang Y; Huang C; Lin S
    J Cell Biochem; 2020 Feb; 121(2):1475-1490. PubMed ID: 31498483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma.
    Liu Z; Liu H; Li Y; Wang Y; Xing R; Mi F; Xiang C; Fu R
    Int J Mol Med; 2020 Apr; 45(4):1112-1120. PubMed ID: 31985020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of p-AKT and p-mTOR in pediatric Burkitt lymphoma and their correlation with prognosis].
    Man J; Chen L; Zhai XW; Ma YY; Wang HS; Qian XW; Feng JY; Zhao J; Cao P; Lu FJ
    Zhonghua Bing Li Xue Za Zhi; 2020 Feb; 49(2):156-161. PubMed ID: 32074729
    [No Abstract]   [Full Text] [Related]  

  • 11. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
    Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
    Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
    Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
    Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation.
    Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Therneau TM; Kyle RA; Greipp PR; Gertz MA
    Am J Hematol; 2001 Dec; 68(4):269-75. PubMed ID: 11754416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients.
    Liontos M; Trigka EA; Korkolopoulou P; Tzannis K; Lainakis G; Koutsoukos K; Kostouros E; Lykka M; Papandreou CN; Karavasilis V; Christodoulou C; Papatsoris A; Skolarikos A; Varkarakis I; Adamakis I; Alamanis C; Stravodimos K; Mitropoulos D; Deliveliotis C; Constantinidis CA; Saetta A; Patsouris E; Dimopoulos MΑ; Bamias A
    World J Urol; 2017 Mar; 35(3):411-419. PubMed ID: 27395374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
    Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
    Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
    Bhatti SS; Kumar L; Dinda AK; Dawar R
    Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic criteria and histologic grading in multiple myeloma: histologic and immunohistologic analysis of 176 cases with clinical correlation.
    Sukpanichnant S; Cousar JB; Leelasiri A; Graber SE; Greer JP; Collins RD
    Hum Pathol; 1994 Mar; 25(3):308-18. PubMed ID: 8150462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma.
    Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J
    Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
    BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
    García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
    PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.